A Phase 2 interventional study of PG4 and 20-valent pneumococcal conjugate vaccine (20vPnC) in Pneumococcal Disease, sponsored by Pfizer. Completed at 39 sites in 2 countries. Open to participants aged 12 Months to 15 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-11.
Sponsored by Pfizer · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Pneumococcal Infections by Pfizer — 4 open to participants now, 8 under way, 5 of them phase 3. Pneumococcal Infections · Pfizer.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 47th largest by enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 in phase 2, and was the 66th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →4 of the 75 studies in Pneumococcal Infections by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 42 days–98 days · Healthy volunteers
Pfizer · Sites in United States, Finland, Poland and 1 more country
Ages 15 mo–17 yrs · Healthy volunteers
Pfizer · Sites in United States, Japan, Puerto Rico
Ages 42 days–211 days · Healthy volunteers
Pfizer · Sites in United States, Argentina, Australia and 8 more countries
Ages 42 days–98 days · Healthy volunteers
By country, each count listing its studies:
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 12 Months to 15 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 9 · Phase 3 33 · Phase 4 7
First in 2001; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 225 is below the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 570 across the 57 interventional studies, 1,050 across the 18 observational. Of the 67 that completed or were terminated, 45 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
4 of the studies in Pneumococcal Infections by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07794748Phase 3PfizerA Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults | 2027-04-26 |
| NCT06622109PfizerA Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months | 2026-12-04 |
| NCT06524414PfizerA Study to Learn About How a New Pneumococcal Vaccine Works in Infants | 2027-03-04 |
| NCT07023081PfizerA Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant | 2027-06-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 75 studies in Pneumococcal Infections by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn about the safety, tolerability and immune effects of a pneumococcal vaccine in toddlers.
Participants will take part in this study for approximately 6 or 8 months depending on which group they are assigned to. During this time participants will have 2 clinic visits and 1 phone visit for the 1-Dose group, or 3 clinic visits and 1 phone visit for the 2-Dose group.
At these clinic visits, participants will be asked if any side effects were experienced. The participants will also have to give blood samples during some clinic visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants to receive a single injection of Multivalent Pneumococcal Vaccine
Biological: PG4
Participants to receive two injections of Multivalent Pneumococcal Vaccine
Biological: PG4
Participants to receive a single injection of 20-valent pneumococcal conjugate vaccine (20vPnC).
Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)
Multivalent pneumococcal conjugate vaccine.
20-valent pneumococcal conjugate vaccine (20vPnC)
Also known as: Prevnar 20
Percentage of participants reporting prespecified local reactions within 7 days after each dose
Prespecified local reactions (redness, swelling, and pain at the injection site) after each dose
Time frame: 7 days after each dose
Percentage of participants reporting prespecified systemic events within 7 days after each dose
Prespecified systemic events (fever, decreased appetite, drowsiness/increased sleep, and irritability) after each dose
Time frame: 7 days after each dose
Percentage of participants reporting Adverse Events (AEs) within 1 month after the last assigned vaccination
Adverse events occurring within 1 month after the last assigned vaccination
Time frame: From signing of ICD to 1 month after last assigned vaccination
Percentage of participants reporting Serious Adverse Events (SAEs) within 6 months after vaccination
SAEs occurring from Dose 1 through 6 months after the last assigned vaccination
Time frame: From signing of ICD to 6 months after last assigned vaccination
Pneumococcal serotype specific IgG concentrations
Pneumococcal IgG GMCs 1 month after the last assigned vaccination
Time frame: 1 month after last assigned vaccination
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jul 2024 to primary completion in Feb 2026, 18 months.
Of 23 phase 2 interventional studies under Pneumococcal Infections, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 18 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.